论文部分内容阅读
为了比较客观地评价丙氟哌酸(CPFX)对感染性肠炎的疗效、安全性等,作者以吡哌酸(PPA)为对照药采用双盲法进行了试验。剂量 CPFX,300mg/d,分3次口服。PPA,2000mg/d,分4次口服。均连用5天。总给药例数为266例(CPFX组:134例,PPA组:132例)。在能判断效果的153例中(CPFX组74例,PPA组79例),对分离菌的MIC值,两组间无显著差异。但对分离出来的志贺氏菌的MIC分布的峰值及MIC_(80)值,CPFX分别为≤0.025μg/ml,0.05μg/ml;PPA各为0.78μg/ml,1.56μg/ml。除菌效果包括带菌者在内的160例(对复杂菌感染病例,每一菌属算作一例,CPFX78例,PPA组82例),CPFX组明显优于对照组(P<0.001)。显效率:CPFX组
In order to objectively evaluate the efficacy and safety of propofol (CPFX) against infectious enteritis, the authors conducted a double-blind trial using piperacillin (PPA) as a control. Dose CPFX, 300mg / d, orally 3 times. PPA, 2000mg / d, 4 times orally. Used for 5 days. The total number of dosing was 266 cases (CPFX group: 134 cases, PPA group: 132 cases). Among 153 cases that can judge the effect (74 cases in CPFX group and 79 cases in PPA group), there was no significant difference in the MIC value of the isolates between the two groups. However, for the isolated MICs of MICs and MICs, the values of CPFX were less than or equal to 0.025μg / ml and 0.05μg / ml respectively, while those of PPA were 0.78μg / ml and 1.56μg / ml respectively. There were 160 cases (including one case of bacterial infection, 78 cases of CPFX and 82 cases of PPA). The CPFX group was significantly better than the control group (P <0.001). Significant efficiency: CPFX group